Genetic variation in the renal sodium transporters NKCC2, NCC, and ENaC in relation to the effects of loop diuretic drugs

Clinical Pharmacology and Therapeutics

Volumn 82, Issue 3, 2007, Pages 300-309

  Vormfelde, S V ^a   Sehrt, D ^a   Toliat, M R ^b   Schirmer, M ^a   Meineke, I ^a   Tzvetkov, M ^a   Nurnberg P ^b   Brockmoller J ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BUMETANIDE; EPITHELIAL SODIUM CHANNEL; FUROSEMIDE; LOOP DIURETIC AGENT; SODIUM CHANNEL; SODIUM CHLORIDE COTRANSPORTER; SODIUM POTASSIUM CHLORIDE COTRANSPORTER; TORASEMIDE; UNCLASSIFIED DRUG;

ADULT; ALLELE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; CROSSOVER PROCEDURE; DIURESIS; DNA POLYMORPHISM; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG URINE LEVEL; GENETIC VARIABILITY; GENOTYPE PHENOTYPE CORRELATION; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEPHRON; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; BUMETANIDE; CROSS-OVER STUDIES; DIURETICS; EPITHELIAL SODIUM CHANNEL; FUROSEMIDE; GENOTYPE; HAPLOTYPES; HUMANS; KIDNEY; MALE; MIDDLE AGED; PHENOTYPE; POLYMORPHISM, GENETIC; POTASSIUM; RECEPTORS, DRUG; SODIUM-POTASSIUM-CHLORIDE SYMPORTERS; SULFONAMIDES; SYMPORTERS; THIAZIDES;

EID: 34547867069     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/sj.clpt.6100131     Document Type: Article

References (39)

1. Vormfelde, S.V., Burckhardt, G., Zirk, A., Wojnowski, L. & Brockmoller, J. Pharmacogenomics of diuretic drugs: data on rare monogenic disorders and on polymorphisms and requirements for further research. Pharmacogenomics 4, 701-734 (2003).
2. Moreno, E. et al. A single nucleotide polymorphism alters the activity of the renal Na+:Cl- cotransporter and reveals a role for transmembrane segment 4 in chloride and thiazide affinity. J. Biol. Chem. 279, 16553-16560 (2004).
3. Tanaka, N. et al. Association of solute carrier family 12 (sodium/ chloride) member 3 with diabetic nephropathy, identified by genome-wide analyses of single nucleotide polymorphisms. Diabetes 52, 2848-2853 (2003).
4. Nishiyama, K. et al. Polymorphism of the solute carrier family 12 (sodium/chloride transporters) member 3, SLC12A3, gene at exon 23 (+78G/A: Arg913Gln) is associated with elevation of urinary albumin excretion in Japanese patients with type 2 diabetes: a 10-year longitudinal study. Diabetologia 48, 1335-1338 (2005).
5. Kim, J.H. et al. SLC12A3 (solute carrier family 12 member [sodium/ chloride] 3) polymorphisms are associated with end-stage renal disease in diabetic nephropathy. Diabetes 55, 843-848 (2006).
6. Matsuo, A. et al. G2736A polymorphism of thiazide-sensitive Na-Cl cotransporter gene predisposes to hypertension in young women. J. Hypertens. 22, 2123-2127 (2004).
7. Matayoshi, T. et al. The thiazide-sensitive Na(+)-Cl(-) cotransporter gene, C1784T, and adrenergic receptor-beta3 gene, T727C, may be gene polymorphisms susceptible to the antihypertensive effect of thiazide diuretics. Hypertens. Res. 27, 821-833 (2004).
8. Samaha, F.F. et al. Functional polymorphism in the carboxyl terminus of the alpha-subunit of the human epithelial sodium channel. J. Biol. Chem. 279, 23900-23907 (2004).
9. Yan, W., Suaud, L., Kleyman, T.R. & Rubenstein, R.C. Differential modulation of a polymorphism in the COOH terminus of the alpha-subunit of the human epithelial sodium channel by protein kinase Cdelta. Am. J. Physiol. Renal Physiol. 290, F279-F288 (2006).
10. Tong, Q., Menon, A.G. & Stockand, J.D. Functional polymorphisms in the alpha-subunit of the human epithelial Na+ channel increase activity. Am. J. Physiol. Renal Physiol. 290, F821-F827 (2006).
11. Ambrosius, W.T. et al. Genetic variants in the epithelial sodium channel in relation to aldosterone and potassium excretion and risk for hypertension. Hypertension 34, 631-637 (1999).
12. Sugiyama, T., Kato, N., Ishinaga, Y., Yamori, Y. & Yazaki, Y. Evaluation of selected polymorphisms of the Mendelian hypertensive disease genes in the Japanese population. Hypertens. Res. 24, 515-521 (2001).
13. Arai, K., Zachman, K., Shibasaki, T. & Chrousos, G.P. Polymorphisms of amiloride-sensitive sodium channel subunits in five sporadic cases of pseudohypoaldosteronism: do they have pathologic potential? J. Clin. Endocrinol. Metab. 84, 2434-2437 (1999).
14. Hsieh, K. et al. Impact of alphaENaC polymorphisms on the risk of ischemic cerebrovascular events: a multicenter case-control study. Clin. Chem. 51, 952-956 (2005).
15. Maitland-van der Zee, A.H. et al. A multilocus approach to the antihypertensive pharmacogenetics of hydrochlorothiazide. Pharmacogenet. Genomics 15, 287-293 (2005).
16. Iwai, N. et al. Association of sodium channel gamma-subunit promoter variant with blood pressure. Hypertension 38, 86-89 (2001).
17. Morris, B., Benjafield, A., Ishikawa, K. & Iawi, N. Polymorphism (-173G>A) in promoter of human epithelial sodium channel gamma subunit gene (SCNN1G) and association analysis in essential hypertension. Hum. Mutat. 17, 157 (2001).
18. Wedlund, P.J., Aslanian, W.S., McAllister, C.B., Wilkinson, G.R. & Branch, R.A. Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism. Clin. Pharmacol. Ther. 36, 773-780 (1984).
19. Cascorbi, I. et al. Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity. Am. J. Hum. Genet. 57, 581-592 (1995).
20. The International HapMap Consortium. Nature 426, 789-796 (2003).
21. Vormfelde, S.V. et al. Hydrochlorothiazide efficacy and polymorphisms in ACE, ADD1 and GNB3 in healthy, male volunteers. Eur. J. Clin. Pharmacol. 62, 195-201 (2006).
22. Schirmer, M. et al. Genetic signature consistent with selection against the CYP3A4*1B allele in non-African populations. Pharmacogenet. Genomics 16, 59-71 (2006).
23. Friedman, P.A. & Gesek, F.A. Stimulation of calcium transport by amiloride in mouse distal convoluted tubule cells. Kidney Int. 48, 1427-1434 (1995).
24. Hoenderop, J.G., Nilius, B. & Bindels, R.J. Calcium absorption across epithelia. Physiol. Rev. 85, 373-422 (2005).
25. Barrett, J.C., Fry, B., Maller, J. & Daly, M.J. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21, 263-265 (2005).
26. Lewontin, R.C. The interaction of selection and linkage. II. Optimum Models. Genetics 50, 757-782 (1964).
27. Zeggini, E. et al. Characterisation of the genomic architecture of human chromosome 17q and evaluation of different methods for haplotype block definition. BMC Genet. 6, 21 (2005).
28. Ding, K. et al. The effect of haplotype-block definitions on inference of haplotype-block structure and htSNPs selection. Mol. Biol. Evol. 22, 148-159 (2005).
29. Zhu, X., Zhang, S., Kan, D. & Cooper, R. Haplotype block definition and its application. Pac. Symp. Biocomput. 152-163 (2004).
30. Gabriel, S.B. et al. The structure of haplotype blocks in the human genome. Science 296, 2225-2229 (2002).
31. Stephens, M. & Donnelly, P. A comparison of bayesian methods for haplotype reconstruction from population genotype data. Am. J. Hum. Genet. 73, 1162-1169 (2003).
32. Stephens, M., Smith, N.J. & Donnelly, P. A new statistical method for haplotype reconstruction from population data. Am. J. Hum. Genet. 68, 978-989 (2001).
33. Sabeti, P.C. et al. Detecting recent positive selection in the human genome from haplotype structure. Nature 419, 832-837 (2002).
34. Walsh, E.C. et al. Searching for signals of evolutionary selection in 168 genes related to immune function. Hum. Genet. 1-11 (2005).
35. Sabeti, P.C. et al. The case for selection at CCR5-Delta32. PLoS Biol. 3, e378 (2005).
36. Vormfelde, S.V. et al. CYP2C9 polymorphisms and the interindividual variability in pharmacokinetics and pharmacodynamics of the loop diuretic drug torsemide. Clin. Pharmacol. Ther. 76, 557-566 (2004).
37. Engelhardt, S., Meineke, I. & Brockmoller, J. Improved solid-phase extraction and HPLC measurement of torasemide and its important metabolites. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 831, 31-35 (2006).
38. Vargo, D.L. et al. Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide and furosemide in patients with congestive heart failure. Clin. Pharmacol. Ther. 57, 601-609 (1995).
39. Rudy, D.W. et al. The pharmacodynamics of intravenous and oral torsemide in patients with chronic renal insufficiency. Clin. Pharmacol. Ther. 56, 39-47 (1994).